IL-6-Dependent PGE2 Secretion by Mesenchymal Stem Cells Inhibits Local Inflammation in Experimental Arthritis

Carine Bouffi1,2, Claire Bony1,2, Gabriel Courties1,2, Christian Jorgensen1,2,3, Danièle Noel1,2*

1 Inserm, Unité 844, Montpellier, France, 2 Université Montpellier 1, Montpellier, France, 3 Service d’Immuno-Rhumatologie Thérapeutique, Hôpital Lapeyronie, Montpellier, France

Abstract

Background: Based on their capacity to suppress immune responses, multipotent mesenchymal stromal cells (MSC) are intensively studied for various clinical applications. Although it has been shown in vitro that the immunomodulatory effect of MSCs mainly occurs through the secretion of soluble mediators, the mechanism is still not completely understood. The aim of the present study was to better understand the mechanisms underlying the suppressive effect of MSCs in vivo, using cells isolated from mice deficient in the production of inducible nitric oxide synthase (iNOS) or interleukin (IL)-6 in the murine model of collagen-induced arthritis.

Principal Findings: In the present study, we show that primary murine MSCs from various strains of mice or isolated from mice deficient for iNOS or IL-6 exhibit different immunosuppressive potential. The immunomodulatory function of MSCs was mainly attributed to IL-6-dependent secretion of prostaglandin E2 (PGE2) with a minor role for NO. To address the role of these molecules in vivo, we used the collagen-induced arthritis as an experimental model of immune-mediated disorder. MSCs effectively inhibited collagen-induced inflammation during a narrow therapeutic window. In contrast to wild type MSCs, IL-6-deficient MSCs and to a lesser extent iNOS-deficient MSCs were not able to reduce the clinical signs of arthritis. Finally, we show that, independently of NO or IL-6 secretion or Treg cell induction, MSCs modulate the host response by inducing a switch to a Th2 immune response.

Significance: Our data indicate that MSCs mediate their immunosuppressive effect via two modes of action: locally, they reduce inflammation through the secretion of anti-proliferative mediators, such as NO and mainly PGE2, and systemically they switch the host response from a Th1/Th17 towards a Th2 immune profile.

Introduction

Multipotent mesenchymal stromal cells or mesenchymal stem cells (MSC) are adult progenitor cells essentially isolated from bone marrow or adipose tissue that can be rapidly expanded ex vivo cells (MSC) are adult progenitor cells essentially isolated from bone marrow or adipose tissue that can be rapidly expanded ex vivo in large numbers. These cells are currently under investigation for tissue engineering applications, in particular for bone and cartilage repair, due to their potential to differentiate into the chondrocyte, osteoblast or adipocyte lineages [1]. Besides their differentiation properties, they may have a therapeutic value in other clinical applications based on their capacity to limit scar formation through anti-fibrotic properties, to prevent apoptosis, to stimulate the regeneration of endogenous cells and to suppress the host immune response (for review, see [2]). These immunosuppressive effects have been shown to occur mainly through the secretion of soluble factors. Among the possible mediators identified, indoleamine 2,3-dioxygenase (IDO) [3], inducible nitric oxide synthase (iNOS) [4–5], heme oxygenase (HO)-1 [6] as well as the secretion of human leukocyte antigen (HLA)-G [7], transforming growth factor (TGF)-β [8], interleukin (IL)-6 [9] and prostaglandin E2 (PGE2) [10] have been postulated to play a role in this process. Depending on the species, immunosuppression mechanisms displayed by MSCs may however differ. For instance, it has been shown that murine MSCs do not possess IDO activity, whereas human MSCs are devoid of iNOS (for review, see [11]). These mechanisms result in the inhibition of the proliferation of CD4+ and CD8+ T cells, B lymphocytes, NK cells that has been mainly shown in vitro but also in vivo in a number of experimental models reviewed in [12].

The therapeutic efficacy of MSCs has been evaluated in experimental autoimmune models, as well as in humans, to prevent acute graft versus host disease (GVHD) [13]. Zappia and collaborators were among the first to report the therapeutic efficacy of MSCs in the experimental autoimmune encephalomyelitis (EAE) [14]. In this murine model of multiple sclerosis, the administration of MSCs was found to decrease the clinical signs...
associated with demyelination when injected before or at disease onset. However, no therapeutic effect was observed when the injection occurred after disease stabilization. Similar results were observed in a model of autoimmune diabetes, where MSC injection promoted repair of pancreatic islets and renal glomeruli, as well as mesangial thickening and reduction in macrophage infiltration resulting in the prevention of pancreatic injury [13].

In collagen-induced arthritis (CIA), an experimental model of rheumatoid arthritis (RA), conflicting results on the role of MSCs have been reported. The first study on the use of MSCs in CIA showed that allogeneic C3H10T1/2 cells did not exert a beneficial effect on disease progression [16]. More recently, it has been demonstrated that systemic injection of MSCs, engineered to constitutively produce IL-10, after the recall of immunization significantly reduced the arthritic symptoms, in contrast to the lack of efficacy of wild type MSCs [17]. Since, it has been reported that a single injection of primary MSCs prevented the development of severe arthritis which was associated with a decreased level of pro-inflammatory cytokine interferon-gamma and an increased frequency of peripheral regulatory T (Treg) cells [18]. Similar results have been obtained in vitro and in vivo with human adipose-derived stem cells (ADSC) that were shown to suppress T cell responses through the generation and activation of antigen-specific Treg cells [19, 20].

The aim of our study was to elucidate the in vivo mechanisms of MSC-mediated immune suppression, in particular the role of IL-6, PGE2 and NO, the function of which is poorly investigated in vivo, and to evaluate their impact on T cell subpopulation in a model of inflammatory autoimmune disease. Contrary to numerous previous reports, we used highly characterized MSCs, either syngeneic or allogeneic and, MSCs deficient in the production of IL-6 or NO that are proposed to play an important role in their immunomodulatory function.

**Results**

**Primary MSCs from different mouse strains are phenotypically and functionally different**

Because most of the in vivo studies reported so far relied on the use of poorly characterized murine MSCs, we decided to use a population of BM-derived cells satisfying the criteria used for MSCs. BM-derived cells, obtained from C57Bl6 or DBA1 mice, were first selected by plastic adherence. A long process of culture expansion was required to obtain a homogeneous cell population of BM-derived cells. Obtained from C57Bl6 or DBA1 mice, were first selected by plastic adherence. A long process of culture expansion was required to obtain a homogeneous cell population of BM-derived cells. Obtained from C57Bl6 or DBA1 mice, were first selected by plastic adherence. A long process of culture expansion was required to obtain a homogeneous cell population of BM-derived cells. Obtained from C57Bl6 or DBA1 mice, were first selected by plastic adherence. A long process of culture expansion was required to obtain a homogeneous cell population of BM-derived cells. Obtained from C57Bl6 or DBA1 mice, were first selected by plastic adherence. A long process of culture expansion was required to obtain a homogeneous cell population of BM-derived cells. Obtained from C57Bl6 or DBA1 mice, were first selected by plastic adherence. A long process of culture expansion was required to obtain a homogeneous cell population of BM-derived cells. Obtained from C57Bl6 or DBA1 mice, were first selected by plastic adherence. A long process of culture expansion was required to obtain a homogeneous cell population of BM-derived cells. Obtained from C57Bl6 or DBA1 mice, were first selected by plastic adherence. A long process of culture expansion was required to obtain a homogeneous cell population of BM-derived cells. Obtained from C57Bl6 or DBA1 mice, were first selected by plastic adherence. A long process of culture expansion was required to obtain a homogeneous cell population of BM-derived cells. Obtained from C57Bl6 or DBA1 mice, were first selected by plastic adherence. A long process of culture expansion was required to obtain a homogeneous cell population of BM-derived cells. Obtained from C57Bl6 or DBA1 mice, were first selected by plastic adherence. A long process of culture expansion was required to obtain a homogeneous cell population of BM-derived cells. Obtained from C57Bl6 or DBA1 mice, were first selected by plastic adherence. A long process of culture expansion was required to obtain a homogeneous cell population of BM-derived cells. Obtained from C57Bl6 or DBA1 mice,
MSC Inhibit Arthritis via PGE2

A

Counts

CD11b | CD14 | CD45 | CD44

Counts

CD73 | CD90 | CD105 | Sca-1

Counts

DBA/1

Counts

CD11b | CD14 | CD45 | CD44

Counts

CD73 | CD90 | CD105 | Sca-1

B

C57Bl/6

Fold increase

d0

d21

OC

AP

Fold increase

PPARγ | aP2

DBA/1

Fold increase

OC

AP

Fold increase

PPARγ | aP2

Fold increase

Col II | Agg

C

% proliferation

basal | 1/2 | 1/20 | ConA

C57Bl/6 MSC

% proliferation

basal | 1/2 | 1/20 | ConA

DBA1 MSC
as the generation and maturation of dendritic cells [9–22] and to be involved in the generation of Treg cells. In order to better evaluate the role of these factors, we derived MSCs isolated from the bone marrow of C57BL/6 mice deficient for iNOS or IL-6, respectively named IL-6−/− and iNOS−/−, and tested their suppressive potential in vitro. IL-6−/− and iNOS−/− MSCs displayed the same phenotypic characteristics and differentiation potential as wild type (wt) B6 MSCs (data not shown). Using a proliferative assay, we found that iNOS−/− and IL-6−/− MSCs were still able to inhibit the proliferation of allogeneic splenocytes, albeit to a significantly lesser extent as compared to wt B6 and D1 MSCs (Fig. 4A). The addition of both iNOS−/− and IL-6−/− MSCs in the proliferative assay did not show any additive effect on the reversion of immunosuppression (data not shown). The immunosuppressive effect was not directly correlated to the secretion of NO as all MSC populations secreted approximately 20 μM NO2, except for iNOS−/− cells (Fig. 4B). NO secretion however was only observed when MSCs were cocultured with activated splenocytes. The secretion of NO2 was inhibited after addition of the specific inhibitor L-NAME. Splenocytes or MSCs did not express basal levels of IL-6. However, except for IL-6−/− MSCs, IL-6 secretion was induced when MSCs were stimulated by activated splenocytes, whereas it was partly inhibited in presence of the COX2 inhibitor indomethacin (Fig. 4C). Production of IL-6 by iNOS−/− MSCs was 5 fold lower than wt B6 MSCs. Secretion of PGE2 was up-regulated by more than 300 fold when splenocytes were incubated with naive MSCs, as compared to basal secretion. iNOS−/− and IL-6−/− MSCs, respectively, secreted 2.5 and 80 fold less PGE2 than wt B6 MSCs (Fig. 4D). Specificity of the PGE2 secretion was confirmed by the neutralization of this production by indomethacin. The production of PGE2 was positively correlated with IL-6 secretion and was inversely proportional to the anti-proliferative effect of the MSCs. This is further correlated by the observation that wt D1 MSCs secreted lower levels of IL-6 and PGE2 and were less immunosuppressive at a MSC:spLENocyte ratio of 1:20 (Fig. 1C). Finally, we checked that IDO was not expressed by murine MSCs, both at the mRNA and protein level, as evaluated by RT-qPCR, spectrophotometric assay and high performance liquid chromatography (data not shown). These results suggest that whereas NO is partly responsible for the anti-proliferative effect of MSCs, IL-6-activated PGE2 secretion mainly participates in this function.

iNOS−/− and IL-6−/− MSCs partially suppress arthritis-associated inflammation

We then compared in vivo the injection of iNOS−/− or IL-6−/− MSCs to that of wt B6 MSCs in the allogenic CIA model. Both deficient cell populations were less efficacious than wt MSCs in decreasing the paw swelling of the arthritic mice and wt MSCs were the only cell population able to significantly reduce the paw swelling of treated mice (Fig. 5A). However, IL-6−/− MSCs, but not iNOS−/− MSCs, were able to induce a significant reversal of immunosuppression as compared to wt MSCs. We therefore investigated whether MSCs were able to inhibit the T cell proliferation and to differentially regulate the involvement of Th1 or Th2 lymphocytes. Irrespective of the nature of the injected MSCs, the bCII-specific response was decreased as assessed by the significantly lower bCII-specific proliferative responses of cells isolated from spleen (Fig. 5B) and draining lymph nodes (DLN) (data not shown). Concomitantly, the bCII-specific IgG1/IgG2a ratio tended to be higher in MSC-treated mice sera than in CIA control sera with no significant differences between groups of MSC-treated mice (Fig. 5C). Serum IL-6, reflecting systemic inflammation, also showed the tendency to decrease in all groups of MSC-treated mice (Fig. 5D).

As naive CD4+ T cells can differentiate into Th1 or Th2 effector cells displaying a distinct cytokine profile, cytokine production levels were thus quantified in supernatants from non activated or bCII-stimulated cells isolated from spleen and DLN. The
production levels of the pro-inflammatory cytokines IL-17 and IFN-γ secreted by splenocytes were unchanged in MSC-treated mice as compared to CIA control mice, except for a significantly higher level of IL-17 in IL-6−/− MSC-treated mice (Fig. 5E). In contrast, a high secretion of the anti-inflammatory cytokines IL-5, IL-10 and IL-13 was detected in spleen of MSC-treated mice as compared to CIA control group, whereas TGF-β1 secretion was not affected (Fig. 5E). Secretion of IL-10 and IL-13 was significantly higher in IL-6−/−-treated group than in wt MSC-treated group, whereas IL-13 production was only increased in
The immunosuppressive effect of MSCs is independent on Treg cell induction

To verify whether the suppressive effect of MSCs was exclusively dependent on the induction of Th2 lymphocytes, we looked for the induction of regulatory cells in spleen and DLN of injected mice. Classical Treg cells are defined as CD4+CD25+Foxp3+ cells although the induction of CD8+CD28+ or CD8+CD28− Treg cells has also been shown to be induced by MSCs [23]. Approximately 12% of cells from spleen and 6% from DLN and PBMC from mice injected or not with MSCs were found to be CD4+CD25+Foxp3+ Treg cells. This percentage was not modified after the administration of MSCs irrespective of their origin (Fig. 6A). Similarly, the percentages of CD8+CD28+ cells (Fig. 6B) or CD8+CD28− cells (approximately 3% in spleen and 0.2% in DLN) were not affected by MSC injection. Because subsets of B lymphocytes or macrophages characterized by IL-10 secretion have been attributed a regulatory function, we investigated whether such cell subsets were induced by MSCs. The proportion of IL-10-producing F4-80+ macrophages and B220+ B lymphocytes was approximately 1% and 50% respectively, among cells from spleen and did not vary following MSC treatment. Finally, the induction of T cell subsets is associated with the up-regulation of subset-specific transcription factors. The expression of transcripts for Foxp3 by Treg cells and GATA-3 by the Th2 subset was thus assessed in splenocytes of the various groups of mice by RT-qPCR. The expression level of GATA-3 tended to be higher in MSC-treated mice, independently of the lack of expression of IL-6 or NO, as compared to the CIA control, while Foxp3 levels remained unchanged between groups (Fig. 6C).

Altogether, the data confirmed that MSCs mediated a therapeutic effect independently of the induction of Treg cell subset and was associated with a polarization of the host immune response into a Th2 profile, independently of IL-6 or NO secretion.

Discussion

The immunosuppressive effect of MSCs is of great interest for the prevention of transplant rejection or graft versus host disease [13,24]. Successful treatment has also been reported in mice with experimental autoimmune diseases, such as CIA or EAE, the animal models of human RA and multiple sclerosis, respectively [14,18]. However, conflicting results on the mechanisms developed by MSCs to suppress inflammation are still under debate. In this study, we relied on the use of MSCs isolated from naïve mice and mice deficient for immunosuppressive molecules to investigate the role of these factors in vitro and in vivo. The main results are i) the differential suppressive effect between MSCs isolated from different mouse strains is only partly dependent on NO and may be mainly attributed to IL-6-activated pathways through PGE2 up-regulation, ii) MSCs display a local intra-articular suppressive effect, in particular through the secretion of IL6-dependent PGE2 and iii) MSCs exert a systemic suppressive effect by mediating a polarization of the host immune response towards a Th2 profile, independently from Treg cell induction or NO and IL-6 secretion.

One important finding of our study is that efficient therapeutic treatment of CIA relies on the injection of MSCs during a narrow window of application (day 18 and 24) as injection of MSCs after disease onset did not prevent the occurrence of arthritic signs. Conflicting results on the therapeutic effect of MSCs have been reported in the CIA model. We and others previously reported that MSC injection failed to reduce arthritis severity [16,17,25,26], in contrast to the results from two other studies that showed a therapeutic benefit [18,20]. The discrepancy between these studies may be related to the source of cells (cell lines versus primary cells).
or various mouse strains, as well as to the dose, route and time of administration. A lack of efficacy of MSC treatment related to the timing of administration has already been reported in a model of GVHD [27]. The authors concluded that factors required for the induction of the immunosuppressive activity of MSCs were not present at the time of injection and that MSC activation was notably dependent on the magnitude of IFN-γ exposure. This is also supported by in vitro results indicating that MSCs may behave as antigen presenting cells in presence of low doses of IFN-γ and thus, rather exacerbate the immune response [28]. In RA physiopathogenesis, TNF-α is the major player in disease onset and in the CIA model, TNF-α secretion increases at day 20 to peak at day 30 [29]. We have previously suggested that TNF-α may inhibit the function of MSCs when the cells were injected on day 21 [16]. Accordingly, it has been shown that TNF-α primarily targets mesenchymal cells resulting in the development of chronic inflammatory polyarthritis and the conditional expression of TNFR1 in these cells is sufficient to induce a fully arthritic phenotype [30,31]. These studies therefore suggest that injected MSCs may be activated by TNF-α and play a role in the pathogenesis of arthritis. In the present study, the injection of MSCs on day 18 is likely to prevent immune cell activation which occurs at boost and in particular, to reduce the secretion of TNF-α. As a result, the activation of endogenous or exogenous mesenchymal cells by TNF-α will not take place, resulting in the inhibition of arthritis development. Immunosuppression requires the presence of MSCs for a time lag sufficient for immune cell education. Indeed, migration of MSCs to target tissues and secondary lymphoid organs where they are able to educate immune cells is likely to be required for efficient therapy. This has not been tested here but would require further investigation as the role of chemokines has been reported to be necessary to the

Figure 5. Immunosuppressive effect of iNOS−/− and IL-6−/− MSCs in experimental arthritis. A) Evaluation of the severity of arthritis by measurement of the increase of the paw swelling of control mice (CIA) or mice injected with wt MSCs, iNOS−/− or IL-6−/− MSCs at d18 and d24 (see arrows). Results are expressed as mean increase ± SEM and representative of three independent experiments (*: p<0.05 between wt MSC-treated group and CIA group; #: p<0.05 between wt MSC-treated group and IL-6−/− MSC-treated group). B) T-cell proliferation assay using splenocytes (10^5 cells) from the various treated mice incubated with 1, 5 or 25 μg/ml of bCII. C) Determination of the ratio of the bCII-specific IgG1/IgG2a by ELISA in mouse sera. Results are expressed as mean ± SEM. D) Quantification of IL-6 by ELISA in the mouse sera. E) Quantification of cytokines secreted by 2×10^6 splenocytes cultured in vitro without activation (dashed histograms) or stimulated with 10 μg/ml bCII (black histograms) for 24 h (IFN-γ and IL-17) or 48 h (others) by ELISA. Results are expressed as the mean ± SEM (*: p<0.05; **: p<0.01; ***: p<0.005; NS: not significant). doi:10.1371/journal.pone.0014247.g005
immunosuppressive effect of MSCs in a model of GVHD [5]. Finally, a recent study demonstrated that MSCs can be polarized into two acting phenotypes classified as MSC1 and MSC2. TLR4-primed MSCs, or MSC1, mostly elaborate pro-inflammatory mediators, while TLR3-primed MSCs, or MSC2, are mostly immunosuppressive [32]. This study provides a possible explanation to some of the conflicting reports on the immune modulating properties of MSCs.

Figure 6. Induction of a Th2 cellular response after treatment with MSCs. A) Percentage of CD4^+CD25^+Foxp3^+ Treg cells in individual spleen, pooled draining lymph nodes (DLN) and individual peripheral blood mononuclear cells (PBMC) from control CIA or MSC-treated mice at day 31. FACS analyses show CD25^+Foxp3^+ cells gated on CD4^+ T cells in the splenocyte population. B) Percentage of CD3^+CD8^+CD28^2 Treg cells in spleen, DLN and PBMC from control CIA or treated mice at day 31. For DLN, cells isolated from all mice in each treated group were pooled resulting in absence of SEM. Results are shown as representative dot plots for 1 mouse per group of mice (upper panel) and histograms in lower panel (% ± SEM), representative of three independent experiments of FACS analyses. C) Relative expression of mRNA level of GATA-3 and Foxp3 transcription factors to GAPDH mRNA in splenocytes using the formula 2^{-ΔΔCt}. Results are expressed as the mean ± SEM (NS: not significant).

doi:10.1371/journal.pone.0014247.g006
In the present study, the therapeutic effect was independent from MHC haplotype since we obtained similar results using syngeneic or allogeneic MSCs. However, previous studies relying on the use of primary MSCs obtained using similar protocols as the one used here, although in different animal models, have shown that allogeneic MSCs may lose their suppressive effect in vivo and, actually, will elicit an immune response from the host [33,34]. To better correlate in vitro and in vivo data, we decided to rely on fully characterized BM-derived primary MSCs which led us to show here that MSCs obtained from different strains of mice do not exhibit the same capacity to inhibit T cell proliferation in vivo. D1 MSCs were less efficient in inhibiting T cell proliferation than B6 MSCs. This was shown in proliferative assays using various ratios of splenocytes versus MSCs and was confirmed using quantitative assays for specific immunosuppressive mediators. This effect was proportional to the levels of IL-6 and PGE2 secreted by the various types of MSCs. Thus, D1 and IL-6−/− MSCs produced the lowest levels of PGE2 and IL-6. The secretion of PGE2 was enhanced proportionally to the expression levels of iNOS by the MSCs. This feedback regulatory loop has already been reported in other model systems [35].

The key role of PGE2 in MSC-mediated immunosuppression is supported by results from a recent study showing that PGE2 represents the key inhibitory mediator of DC differentiation and maturation and as a consequence, of reduced T cell activation [36]. Moreover, MSC-derived PGE2 was reported to act on macrophages, increasing their IL-10 secretion and reducing inflammation [10]. We have observed that MSCs promote in vitro the secretion of IL-10 by macrophages. We also showed that in vitro, iNOS−/− MSCs were less suppressive than wt MSCs. However, these cells secreted lower levels of IL-6 and PGE2 as compared to wt MSCs, making it difficult to appreciate the role of individual molecules. This finding was consistent with recent results showing inhibition of IL-6 and PGE2 after inhibition of NO in cartilage [37]. IL-6 seems to be the central player since it is induced by PGE2 [38] but IL-6 also positively regulates both COX2 and iNOS activities [22,39]. Indeed, in absence of IL-6 both NO and PGE2 production are reduced. In our model in vitro, NO secretion was however poorly impaired by loss of IL-6. Therefore in vitro, we showed that iNOS−/− MSCs exert a lower suppressive activity than wt MSCs. Using IL-6−/− MSCs, we demonstrated that IL-6-dependent PGE2 secretion is correlated with the immunosuppressive activity of MSCs suggesting that PGE2 is the major mediator of immunosuppression.

In the CIA model, we confirmed the role of IL-6 and PGE2 in the suppressive activity of MSCs since IL-6−/− MSCs exhibited the lowest suppressive effect and did not significantly reduce the severity of arthritis as compared to wt MSCs. Decreased IL-6-dependent PGE2 secretion could account for this effect as observed in vitro through its role on T cell proliferation, macrophage reprogramming or DC maturation [40,41,42]. Here, the effect of MSC-mediated iNOS activity was marginal since iNOS−/− MSCs behave similarly as wt MSCs. This result differs from another study in the experimental model of GVHD [5]. The authors however principally used MSC clones which behave differently from populations since the clones did not secrete PGE2. It could be hypothesized that the inability of iNOS−/− MSCs to suppress immune responses may be the result of their impaired function to secrete both NO and PGE2 which may be mediators with complementary immunosuppressive functions. Therefore, using for the first time IL-6-deficient MSCs, we confirmed in vivo that MSC immunosuppression was mainly dependent on IL-6-activated signalling pathways although this effect was partial and that, PGE2 is likely to be the mediator acting downstream in the MSC-mediated immunomodulation.

Surprisingly, the clinical differences observed using various MSC types were not concordant with the biological responses since the evaluation of local and systemic immune responses of MSC-treated mice revealed similar profiles, irrespective of their production of either NO or IL-6. We observed a decreased bCII-specific T cell proliferative response, an increased bCII-specific IgG1/IgG2a ratio and low levels of pro-inflammatory mediators, as well as increased levels of anti-inflammatory cytokines in bCII-primed T lymphocytes from spleen. All these parameters are characteristic of a Th2 immune profile which was further confirmed by the increase in GATA-3 mRNA levels in splenocytes from MSC-treated animals. These data were not consistent with those of a previous study indicating that secretion of IL-10 and IL-4 was down-regulated [18]. In the latter study however, MSCs were cultured in vitro with T lymphocytes isolated from immunized mice and challenged with bCII for 2 days. Because a Treg cell-dependent mechanism of suppression has been proposed in CIA [18,20,43], we investigated the increase of CD4+CD25+Foxp3+, CD3+CD68+CD28− or CD3+CD8+CD28− cells in spleen, DLN and blood. No significant increase of these T cell populations was observed and no changes in TGF-β1 secretion levels or in Foxp3 mRNA expression were observed in splenocytes, further suggesting that no Treg cells were induced. The discrepancy between previous results and those reported here may arise from the time and route (intra-peritoneal versus intravenous) of MSC administration leading to variable immune responses. Interestingly, injection of CD4+CD25− Treg cells did not alter bCII-specific antibody secretion or T cell proliferative response while markedly slowing CIA progression [44]. Our results demonstrating altered bCII-specific T and B cell responses are not in line with the hypothesis of Treg cell induction but are in concordance with this last study. Lack of Treg cell induction by MSCs was also reported in autoimmune enteropathy [45] and EAE [14]. In the latter study, the authors detected a slight down-regulation of CD40 and MHC class II molecules on DCs, suggesting that impaired co-stimulation by DCs from treated mice could contribute to peripheral T cell anergy. Alternatively, secretion of PGE2 by the injected MSCs may impair the maturation of DCs and therefore may account for a switch towards a Th2 immune response profile, as already reported in previous studies [40,41,42]. Indeed, anti-proliferative mediators such as NO and more importantly, IL-6-dependent PGE2 may act locally by inhibiting the proliferation of immune cells in the synovium thereby reducing local inflammation. Altogether, our results suggest that NO or PGE2 mediators may act together to decrease local inflammation but that the main effect of MSCs is likely on systemic immunity through a polarization of the host immune response towards a Th2 cytokine production profile.

This study demonstrates that MSCs might be used for regulating inflammatory responses and could offer therapeutic benefit in autoimmune diseases. Like Treg cells, MSCs migrate to the joints where they can act locally inside the inflamed synovium to decrease the proliferation and function of immune cells via the secretion of inhibitory soluble factors. They can also act systemically to suppress the host immune response through a shift in the Th1/Th2 cell balance, indicating that MSC-induced immune suppression is not mediated by a single or unique mechanism. This may have important therapeutic applications far beyond the field of autoimmune diseases.
Materials and Methods

Isolation of stromal cells

MSCs from C57BL/6 or DBA/1 mice or from iNOS- or IL-6-knock-out C57BL/6 mice were isolated from bone marrow (BM). BM was flushed out from long bones and the cell suspension (0.5×10^6 cells/cm^3) was plated in minimum essential medium (MEM)-10% fetal bovine serum (FBS) (Hyclone, Thermo Fisher Scientific, Brebières, France), 2 mM glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin (Lonza, Levallois-Perret, France) and 2 ng/mL human basic fibroblast growth factor (bFGF) (R&D Systems, Lille, France). At sub-confluence, cells were collected, propagated at a density of 5,000 cells/cm^2 and used between passages 6 and 10.

Differentiation of MSCs

Differentiation of MSCs was induced by culture under specific conditions for 21 days. For adipogenesis, MSCs were plated at 10^5 cells/cm^2 in complete Dulbecco’s modified Eagle’s medium (DMEM-F12 (Invitrogen) with 10% fetal bovine serum (FBS) with 16 μM biontin, 18 μM panthenolic acid, 100 μM ascorbic acid, 5 μg/mL insulin, 0.03 μM dexamethasone, 1 μg/mL transferring, 2 ng/mL triiodothyronine (T3) and 100 nM rosiglitazone (Sigma-Aldrich, Saint-Quentin Fallavier, France). Formation of lipid droplets was visualized by Oil red O staining on cells fixed by 3% glutaraldehyde for 1 h. For osteogenesis and chondrogenesis, inductive conditions were already reported [46]. Chondrogenesis was assessed by RT-qPCR and immunohistochemistry on paraffin sections of pellets using the formula 2^−ΔΔCt or as fold increase using the formula 2^−ΔCt or as fold increase using the formula 2^−ΔΔCt

RT-qPCR analysis

Total RNA was extracted using the RNeasy mini kit (Qiagen S.A., Courtaboeuf, France). RNA (500 ng) was then reverse transcribed using the Multiscribe reverse transcriptase and PCR was done with the GeneAmp® RNA PCR Core Kit using the "Assays-on-Demand" gene expression assays (Applied Biosystems, Courtaboeuf, France) on the Lightcycler 480 (Roche Applied Systems, Meylan). cDNA samples was normalized to the expression of GAPDH mRNA and expressed either as relative expression to GAPDH mRNA using the formula 2^−ΔΔCt or as fold increase using the formula 2^−ΔCt

Flow Cytometry analysis

MSCs (5×10^5) were suspended in phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin and 0.01% sodium azide and incubated for 20 min on ice with conjugated monoclonal antibodies. Specific and isotypic control antibodies were from BD Biosciences (Le Pont de Claix, France). Mononuclear cell suspensions were isolated after dissociation of spleens and draining lymph nodes or from blood after Ficoll separation as described elsewhere [47]. For membrane staining, cells were incubated with anti-mouse conjugated antibodies or F4-80 or B220 conjugated antibodies (BD Biosciences) as described above. For Foxp3 intracellular staining, cells were incubated in 150 μl/well of Fix/Perm solution overnight at 4°C and then at 4°C for 15 min with permeabilization buffer (Cliniscience, Montrouge, France), followed by incubation with anti-Foxp3 antibody for 30 min on ice (Miltenyi Biotec, Paris, France). Flow cytometry was performed on a fluorescence activated cell sorter (FACSCalibur), and data analysed with the CellQuestPro software (BD, Le Pont de Claix, France).

Measurement of IDO and iNOS Activities

IDO enzyme activity was measured after MSC stimulation with 1000 U/ml IFN-γ for 48 hours as reported [46,48].

Because nitric oxide (NO) is quickly converted to NO2 and NO3 in culture medium, NO2 production was measured using a modified Griess reagent (Sigma-Aldrich) as described previously [49].

Quantification of cytokines

Enzyme-linked immunosorbent assays (ELISA) were performed using the CellTiter-GloTM luminescent cell viability assay (Promega, Charbonnières-les-Bains, France). MSC Inhibit Arthritis via PGE2

Arthritis induction and measurement

Adult male DBA/1 mice aged 9–10 weeks were grown in our animal facilities. All animal experiments complied with the regulations of the Ethical Committee of the Languedoc-Roussillon. Approval CEEA-LR-1042 (Comité Régional d’éthique pour l’Expérimentation animale, Languedoc Roussillon). Immunization was performed as reported in [16] and MSCs (1×10^5 cells) were injected intravenously on day 18 and 24, otherwise indicated. Signs of arthritis were assessed by measuring the paw swelling of the hind paw and evaluating the clinical score using the macroscopic scale as previously described [16]. After sacrifice, the hind limbs were collected for X-ray and radiological scoring was performed as described [51].

Histology and immunohistochemistry

The paws were fixed in 4% paraformaldehyde, decalcified overnight in Rapid Bone Decalcifier (Eurobio, Les Ulis, France) and processed for routine histology. Histological scoring was
performed on hematoxylin/eosin/safranin O sections as follows: 0, normal; 1, inflammatory infiltrates and synovial hyperplasia; 2, pannus formation and cartilage erosion; 3, important cartilage erosion and bone destruction, 4, loss of joint integrity.

Statistical analysis
Statistics were done using the Student t test and for in vivo experiments, with an impaired Mann-Whitney test to compare nonparametric data for statistical significance.

Acknowledgments
We thank T. Billiar and D. Williams (University of Pittsburgh School of Medicine, Pittsburgh, USA) for providing bones from iNOS knock-out mice and S. Jones (The School of Medicine, Cardiff, UK) for bones from IL-6 knock-out mice. MSCs were isolated from the bone marrow of long bones of these knock-out mice. We are grateful to K. Tarte (InsERM U917, Remes, France) for IOD activity measurement by high performance liquid chromatography. The authors thank the breast radiography group, head by Pr Taourel, from Lapeyronie Hospital in Montpellier who performed the radiographies.

Author Contributions
Conceived and designed the experiments: CJ DN. Performed the experiments: C. Bouffi C. Bony GC. Analyzed the data: C. Bouffi C. Bony GC DN. Wrote the paper: C. Bouffi DN.

References
1. Vinaiier C, Murgula D, Jorgensen C, Guich eux C, Noel D (2009) Cartilage engineering: a crucial combination of cells, biomaterials and biofactors. Trends Biotechnol 27: 307–314.
2. Djouad F, Bouffi C, Ghannam S, Noel D, Jorgensen C (2009) Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol 5: 399–392.
3. Spaggiari GM, Cabobianco A, Abdelrazik H, Becchetti F, Mingari MC, et al. (2008) Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111: 1327–1333.
4. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, et al. (2007) Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109: 228–234.
5. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, et al. (2008) Mesenchymal stem cell mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2: 141–150.
6. Chabannes D, Hill M, Merieau E, Rossignol J, Brion R, et al. (2007) A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 110: 3691–3694.
7. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, et al. (2008) Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer cell function and to induce CD4+CD25high FOXP3+ regulatory T cells. Stem Cells 26: 212–222.
8. Bartholomeu A, Patil S, Mackay A, Nelson M, Buyaner D, et al. (2001) Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther 12: 1527–1541.
9. Nauta AJ, Mrugala D, Jorgensen C, Guicheux J, Noel D (2009) Cartilage repair using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in osteoarthritic cartilage–mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production. Arthritis Rheum 56: 1175–1186.
10. van den Bussche H, Noman M, Rondeau P, Miossec P, Moreau P, et al. (2008) Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 205: 297–302.
11. Ghannam N, Bouffi C, Djouad F, Jorgensen C, Noel D (2010): Immunosuppression by mesenchymal stem cell mechanisms: clinical applications. Stem Cell Res Ther 1: 2.
12. Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8: 726–736.
13. Le Blanc K, Frassoni F, Ball L, Locatelli F, Koelsch H, et al. (2008; Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371: 1579–1586.
14. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, et al. (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell recovery. Am J Physiol Regul Integr Comp Physiol 291: R1316–1326.
15. Lee RR, Seo MJ, Reger RL, Spears JL, Pulin AL, et al. (2006) Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal parenchyma in diabetic NOD/SCID mice. Proc Natl Acad Sci U S A 103: 17438-17443.
16. Djouad F, Fritz V, Apparailly F, Losier-Pence E, Bouy C, et al. (2005) Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor-alpha in collagen-induced arthritis. Arthritis Rheum 52: 1593–1603.
17. Choi JJ, Yoo SA, Park SJ, Kang YJ, Kim WP, et al. (2008) Mesenchymal stem cell overexpressing interleukin-10 attenuate collagen-induced arthritis in mice. Clin Exp Immunol 153: 269–276.
18. Augello A, Tasso R, Negrini SM, Cancereda R, Pennesi G (2007) Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 56: 1175–1186.
19. Gonzalez-Rey E, Gonzalez MA, Varela N, O’Valle F, Hernandez-Gortes P, et al. (2009) Human adipose-derived mesenchymal stem cells reduce inflammatory and T-cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis.
40. Shibata Y, Henriksen RA, Honda I, Nakamura RM, Myrvik QN (2005) Splenic PGE2-releasing macrophages regulate Th1 and Th2 immune responses in mice treated with heat-killed BCG. J Leukoc Biol 78: 1281–1290.
41. Son Y, Ito T, Ozaki Y, Tanjiri T, Yokoi T, et al. (2006) Prostaglandin E2 is a negative regulator on human plasmacytoid dendritic cells. Immunology 119: 36–46.
42. Woolard MD, Wilson JE, Hendley LL, Jania LA, Kawala TH, et al. (2007) Francisella tularensis-infected macrophages release prostaglandin E2 that blocks T cell proliferation and promotes a Th2-like response. J Immunol 178: 2065–2074.
43. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A (2007) Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92: 881–888.
44. Morgan ME, Flierman R, van Duivenvoorde LM, Witteveen HJ, van Ewijk W, et al. (2005) Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum 52: 2212–2221.
45. Parkkadan B, Tilles AW, Yarmush ML (2008) Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells 26: 1913–1919.
46. Djouad F, Bony C, Haupl T, Uze G, Lahlou N, et al. (2005) Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells. Arthritis Res Ther 7: R1304–1315.
47. Charbonnier LM, van Duivenvoorde LM, Apparailly F, Cantos G, Han WG, et al. (2006) Immature dendritic cells suppress collagen-induced arthritis by in vivo expansion of CD49b+ regulatory T cells. J Immunol 177: 3806–3813.
48. Daubener W, Huckle C, Seidel K, Hadding U, MacKenzie CR (1999) Interleukin-1 inhibits gamma interferon-induced bacteriostasis in human uroepithelial cells. Infect Immun 67: 3615–3620.
49. Miranda KM, Espey MG, Wink DA (2001) A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5: 62–71.
50. Perez N, Plence P, Millet V, Greuet D, Minot C, et al. (2002) Tetracycline transcriptional silencer tightly controls transgene expression after in vivo intramuscular electrotransfer: application to interleukin 10 therapy in experimental arthritis. Hum Gene Ther 13: 2161–2172.
51. Apparailly F, Versaercede C, Jaquet C, Auriault C, Sany J, et al. (1998) Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol 160: 5213–5220.